Therapeutic Indications

Acalabrutinib is indicated for:

Small lymphocytic lymphoma (SLL)

Irrespective of gender only Adults (18 years old or older)

Acalabrutinib is indicated for the treatment of adult patients with small lymphocytic lymphoma (SLL).

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 200 mg in 2 divided doses daily

Mantle cell lymphoma (MCL)

Irrespective of gender only Adults (18 years old or older)

Acalabrutinib is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 200 mg in 2 divided doses daily

Chronic lymphocytic leukaemia (CLL)

Irrespective of gender only Adults (18 years old or older)

Acalabrutinib is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL).

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 200 mg in 2 divided doses daily

Contraindications

Active ingredient Acalabrutinib is contraindicated in the following cases: